March 9, 2012 — Researchers have developed a method to label transplanted cells so they can be tracked by magnetic resonance imaging (MRI). In the future, as cell therapies become a more integral part of regenerative medicine and tumor treatment, there could be increased need to measure how many transplanted immune or stem cells reach their target.

March 8, 2012 — Transgenomic Inc. announced the publication of a new study by researchers at Vanderbilt University that further validates the role of both genes found in the company’s PGxPredict: Clopidogrel (Plavix) Panel, a comprehensive test to predict a patient’s response to clopidogrel (Plavix).

March 8, 2012 — Researchers at Sentara Cardiovascular Research Institute are among the top enrollers out of 69 leading heart centers in the United States involved in a clinical trial designed to use a new investigational device to evaluate the safety and efficacy of a physician-directed patient self-management system.

March 8, 2012 — Edwards Lifesciences Corp. reported March 3 it filed its official response to the Centers for Medicare and Medicaid Services (CMS) on its proposed national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR).

March 7, 2012 — Critical Diagnostics announced results from a multi-center study in ambulatory heart failure patients which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events compared to the Seattle Heart Failure Model (SHFM).

March 7, 2012 — The U.S. Patent and Trademark Office (USPTO) granted biopharmaceutical development company BioLineRx for a new medical device for prevention of cardiac remodeling following an acute myocardial infarction (AMI). Additional patents claiming for the BL-1040 device composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.

March 7, 2012 — The U.S. Food and Drug Administration (FDA) cleared the Abbott Absolute Pro vascular self-expanding stent system for use in iliac artery peripheral artery disease (PAD) lesions.

March 7, 2012 — Covidien announced the global launch of the Optivantage dual-head computed tomography (CT) contrast media delivery system with simultaneous injection.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now